clofazimine
3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Machine-generated and unreviewed. Identity, structure and cross-references come straight from ChEBI's and CARD's own data; no curator has signed off on this record yet.
Classification
antibiotic without defined classificationARO:3000003
-
CHEBI:39201 -
CHEBI:83403 - antibiotic without defined classification
ARO:3000003
Chemical structure
| Molecular formula | C27H22Cl2N4 |
|---|---|
| Charge | 0 |
| Average mass | 473.407 Da |
| Monoisotopic mass | 472.12215 Da |
| Source | ChEBI |
| InChIKey | WDQPAMHFFCXSNU-UHFFFAOYSA-N |
CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1
InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
Also called
- clofazimina
- clofaziminum
- N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine
- (4-Chloro-phenyl)-[5-(4-chloro-phenyl)-3-isopropylimino-3,5-dihydro-phenazin-2-yl]-amine
- 3-(p-chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine
- 3-(p-chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin
- N,5-bis(4-chlorophenyl)-3-(isopropylimino)-3,5-dihydrophenazin-2-amine
- Lampren
- Lamprene
Cross-references
- clofazimine
ARO:3004012 - beilstein:8168151
- cas:2030-63-9
- kegg.compound:C06915
- lincs.smallmolecule:LSM-5669
- chembl:CHEMBL1292
- pubchem.compound:2794
Drug registries
Patents and articles
Activity roles
- leprostatic drug
CHEBI:35816
Source concepts
| Source | Native ID | Label | Minted CURIE | Version |
|---|---|---|---|---|
| ARO | ARO:3004012 |
clofazimine | antibioticmech:aro-2f5364eabc |
2026-08-30 |
| CHEBI | CHEBI:3749 |
clofazimine | antibioticmech:chebi-fa5f5dc8e5 |
2026-08-30 |
Molecular targets
fluoroquinolone sensitive gyrA PROTEIN DIRECT_BINDING_TARGET
fluoroquinolone sensitive gyrB PROTEIN DIRECT_BINDING_TARGET
Activity spectrum
| Organism | Activity | MIC | Disk diffusion | Assay | Strain | Sample/genome | Evidence |
|---|---|---|---|---|---|---|---|
| Mycobacterium tuberculosis complex | RESISTANT | — | — | CRyPTIC DST; CLIRES2020; liquid media; MGIT; MGIT960 | — |
18 source isolates 18 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | — | — | CRyPTIC DST; CLIRES2020; liquid media; MGIT; MGIT960 | — |
4366 source isolates 4366 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | RESISTANT | — | — | CRyPTIC DST; CLIRES2020; not specified | — |
2 source isolates 2 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | — | — | CRyPTIC DST; CLIRES2020; not specified | — |
2 source isolates 2 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | INTERMEDIATE | — | — | CRyPTIC DST; CLIRES2020; solid media | — |
1 source isolates 1 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | RESISTANT | — | — | CRyPTIC DST; CLIRES2020; solid media | — |
32 source isolates 32 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | — | — | CRyPTIC DST; CLIRES2020; solid media | — |
63 source isolates 63 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | RESISTANT | — | — | CRyPTIC DST; CLIRES2023; liquid media; MGIT; MGIT960 | — |
8 source isolates 8 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | — | — | CRyPTIC DST; CLIRES2023; liquid media; MGIT; MGIT960 | — |
858 source isolates 858 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | — | — | CRyPTIC DST; CLIRES2023; not specified | — |
1 source isolates 1 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | RESISTANT | — | — | CRyPTIC DST; CLIRES2023; solid media | — |
7 source isolates 7 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | — | — | CRyPTIC DST; CLIRES2023; solid media | — |
4 source isolates 4 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | 0.12 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
1151 source isolates 1151 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | 0.12 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
217 source isolates 217 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | 0.12 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
257 source isolates 257 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | 0.25 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
410 source isolates 410 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | 0.25 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
160 source isolates 160 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | SUSCEPTIBLE | 0.25 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
101 source isolates 101 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | RESISTANT | 0.5 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
113 source isolates 113 measurements |
EvidencePage data (JSON.gz) |
| Mycobacterium tuberculosis complex | RESISTANT | 0.5 mg/L | — | CRyPTIC DST; CRyPTIC; liquid media; microdilution plate; UKMYC5; critical concentration 0.25 mg/L | — |
54 source isolates 54 measurements |
EvidencePage data (JSON.gz) |
Resistance mechanisms
ANTIBIOTIC_TARGET_ALTERATION 3
| Determinant | ARO ID | Organism | Gene families | Evidence |
|---|---|---|---|---|
| Mycobacterium tuberculosis Rv0678 with mutation conferring resistance to clofazimine | ARO:3007852 | — | ||
| Mycobacterium tuberculosis Rv2535c with mutation conferring resistance to bedaquiline | ARO:3007692 | — | ||
| Mycobacterium tuberculosis Rv2535c with mutation conferring resistance to clofazimine | ARO:3009335 | — |
Curation history
-
SEEDED_FROM_SOURCES
Seeded from data/raw/ inventories (ARO, CHEBI)
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded; changed: activity_spectrum (CRYPTIC 3.4.0). Upstream retrieval date 2026-08-30, unchanged.
-
RESEEDED_FROM_SOURCES
Re-seeded; changed: activity_membership_collections (CRYPTIC 3.4.0). Upstream retrieval date 2026-08-30, unchanged.